0001209191-20-052231.txt : 20200928 0001209191-20-052231.hdr.sgml : 20200928 20200928172545 ACCESSION NUMBER: 0001209191-20-052231 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200928 FILED AS OF DATE: 20200928 DATE AS OF CHANGE: 20200928 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lin Shao-Lee CENTRAL INDEX KEY: 0001725092 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38653 FILM NUMBER: 201205374 MAIL ADDRESS: STREET 1: C/O HORIZON PHARMA PLC STREET 2: CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD CITY: DUBLIN STATE: L2 ZIP: 4 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Principia Biopharma Inc. CENTRAL INDEX KEY: 0001510487 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263487603 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 220 EAST GRAND AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 416-7700 MAIL ADDRESS: STREET 1: 220 EAST GRAND AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-09-28 1 0001510487 Principia Biopharma Inc. PRNB 0001725092 Lin Shao-Lee C/O PRINCIPIA BIOPHARMA INC. 220 E. GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Director Stock Option (right to buy) 27.81 2020-09-28 4 D 0 20475 D 2029-04-15 Common Stock 20475 0 D Director Stock Option (right to buy) 31.77 2020-09-28 4 D 0 10240 D 2029-06-10 Common Stock 10240 0 D Director Stock Option (right to buy) 62.66 2020-09-28 4 D 0 10240 D 2030-06-03 Common Stock 10240 0 D Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. /s/ Christopher Y. Chai, Attorney-in-Fact for Shao-Lee Lin 2020-09-28